Thermocoagulation in Drug Resistant Focal Epilepsy

N/AActive Not RecruitingNCT05248269

State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia75 enrolled

Overview

Therapeutic thermocoagulation will be carried out in patients with drug-resistant focal epilepsy in cases where an epileptogenic zone is found and proven according to stereo-electroencephalography (SEEG) data.

Open-label, pilot, non-comparative, interventional cohort study. Each patient will be examined at least 8 times (8 visits will pass): Visit 0 - screening (within 14 days before Visit 1), Visit 1 (visit includes the procedure for the destruction of the epileptogenic focus), Visits 2 and 3 (after 1 and 2 days after Visit 1) - a repeated procedure for the destruction of the epileptogenic focus with an incomplete effect of the first procedure (not mandatory, carried out by the decision of the principal investigator), Visits 4-7 (7, 14, 30, 180 days after the procedure for the destruction of the epileptogenic focus). Patients will be divided into 4 cohorts of 4 patients. Enrollment in the study of the next cohort of patients will be based on the safety analysis of the previous cohort 1 day after the manipulation. After assessing the position of the electrodes based on the conjugation of brain MRI data before and after SEEG implantation and seizure recording, the ictal zone is determined. Thus, the localization of pathological activity is determined on the basis of neuroimaging data, as well as in accordance with the activity under certain contacts of the SEEG electrodes. After explaining the treatment options to the patient and relatives, informed voluntary consent is taken for the implementation of this procedure. Using a radio frequency generator Cosman RFG-G4, destruction is carried out at the necessary electrode contacts with a power of 3W, exposure time of 180 sec. In case of pain occurrence, the procedure is immediately terminated. After the procedure, the patient continues SEEG monitoring for 3 days. If additional epileptogenic zones are identified, if necessary, a repeated thermocoagulation is performed (on the 2nd and 3rd days of the study). If there is no need for a second thermocoagulation, then Visits 2 and 3 are not performed. Next, the patient undergoes removal of the electrodes, a control MRI study is performed. Follow-up includes follow-up for 6 months. Visits 4-6 involve phone interviews with patients. During the conversation, the researcher should clarify complaints, general well-being, the presence and frequency of epileptic seizures over the period of time that has passed since the previous visit.

Study Type

INTERVENTIONAL

Allocation

Conditions

Epilepsy Seizures, Focal Epilepsy Intractable Epilepsies, Partial

Interventions

Radiofrequency thermocoagulationPROCEDURE

The 2 pertinent contacts connect to Radiofrequency thermocoagulation lesion-generator equipment (Cosman G4 with Ad-tech electrodes), expressly modified for use with SEEG electrodes. The following parameters will be adopted: current power 3 W within 180 seconds and current intensity (usually approximately 25 mA) variable according to impedance.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Diagnosis of symptomatic drug-resistant epilepsy according to anamnesis, results of video EEG monitoring with registration of epileptic seizures. 2. The epileptogenic zone verified using invasive electrodes. 3. The patient has read the information sheet and signed the informed consent form. Non-inclusion Criteria: 1. Persons with mental disorders. 2. Women during pregnancy, childbirth. 3. Women during breastfeeding. 4. Reception of anticoagulants. 5. Location of the epileptogenic focus within functionally significant areas, large vessels of the brain. 6. Primary generalized forms of epilepsy. Exclusion Criteria: 1. Absence of a registered seizure on stereo-EEG. 2. Absence of a focal pattern during invasive stereo-EEG monitoring. Dropout Criteria: 1. Refusal of the patient from observation 2. The occurrence of contraindications that may prevent participation in diagnostic and treatment activities. 3. Unwillingness or inability of the patient to comply with the requirements of the protocol, including the presence of any condition (physical, mental or social) that may affect his ability to comply with the requirements of the study 4. Identification of conditions during the study that meet the exclusion criteria for non-inclusion of patients. 5. Lack of effect from thermocoagulation within a month after manipulation or worsening of the condition associated with an increase in the number/severity of epileptic seizures.

Locations (1)

Pirogov National Medical and Surgical Center

Moscow, Russia

Outcomes

Primary Outcomes

Severe adverse reactions and events rate

Severe adverse reactions and events will be monitored and registered during procedure of thermocoagulation and up to 6 months after procedure

Time frame: Up to 6 months after procedure

Seizure freedom or reduction after procedure

The incidence of seizures will be assessed and registered daily by patient in the diary for self-inspection. Records in the diary will be inspected by investigators during follow-up visits.

Time frame: Up to 6 months after procedure

Secondary Outcomes

Three-level European quality of life five-dimensional questionnaire

There are five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. Patients choice results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describe the health status.

Time frame: Up to 6 months after procedure

Pittsburgh Sleep Quality Index (PSQI) Questionnaire

The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire that assesses sleep quality over a 1 month time frame. It consists of 19 individual elements, making up 7 components that give one overall rating. Each item is weighted on a scale from 0 to 3. The overall PSQI score is then calculated by adding the scores of the seven components to give an overall score of 0 to 21, where lower scores mean healthier sleep quality.

Time frame: Up to 6 months after procedure

Change of epileptiform activity on electroencephalography (EEG) study

EEG will be registered and reduction of epileptiform activity will be assessed (Beta, Theta, spikes, sharp waves).

Time frame: Days 1, 7, 180

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.